Chicago, United States
Emalex Biosciences is a pioneering biotech company dedicated to enhancing lives through significant scientific innovations in the realm of central nervous system disorders. Established in 2018, this United States-based company is at the forefront of developing a novel drug class targeting Tourette syndrome and other neurological conditions. Operating within the dynamic sectors of Biopharma, Biotechnology, Health Care, and Pharmaceuticals, Emalex is positioned as a leading entity in its industry.
The company's most recent funding round comprised a substantial $250.00M Series D investment secured on 01 November 2022, underlining strong investor confidence. Notable contributors to this round included heavyweights like Valor Equity Partners, Paragon Biosciences, Fidelity Investments, and Bain Capital Life Sciences. These partnerships underscore Emalex’s potential to achieve groundbreaking advancements in its drug development pursuits.
Xanthus Pharmaceuticals